The Virginia Bioscience Health Research Corporation (the “Catalyst”) is an innovative, non-profit entity, created by the Commonwealth to accelerate commercialization of breakthrough technologies from our research universities that improve human health and drive economic development in Virginia. This is achieved by incentivizing Virginia's research universities to work together and to work with industry to achieve competitive critical mass through collaborations that attracts new capital from sources both inside and outside Virginia. VBHRC provides grants to projects that: 1) include a substantive collaboration among two or more of Virginia public research universities and industry partners; 2) address major unmet medical needs that will improve human health; 3) have national and global competitive advantages including IP protection; 4) have matching funds and 5) can demonstrate significant positive impact potential for economic development in Virginia.
Nearly a dozen grants have been made to competitively judged projects across the state, and across fields and disciplines in the biosciences. The CEO of the Catalyst and leaders of select collaborations which have received grants will share important research breakthroughs, successes in follow-on financing, report on progress in commercializing their technologies, provide return on investment data and summarize the impact of this innovative public policy initiative.
Please join us in this panel discussion which will include significant participation from attendees. If you are a research scientist who wants to commercialize your technologies, an entrepreneur, venture capitalist or a public policy influencer or decision maker you should attend this session. This session is expected to sell out, so please register early.
- Dr. Gautam Ghatnekar, President and CEO, FirstString Research, Inc.
- Robert G. Gourdie Ph.D., Professor and Commonwealth Research Commercialization Fund Eminent Scholar, VTCRI, Director of the Center for Heart and Regenerative Medicine, VTCRI, Director of Emergency Medicine Research, Carilion Clinic, Professor; Virginia Tech Wake Forest University School of Biomedical Engineering and Sciences
- Michael Grisham, President & CEO, Virginia Biosciences Health Research Corporation
- Jerry L. Nadler, MD, FAHA, MACP, Harry H. Mansbach Professor and Chair, Department of Medicine, Vice Dean for Research, Eastern Virginia Medical School
- Emanuel "Chip" Petricoin Ph.D., University Professor, Co-Director Center for Applied Proteomics and Molecular Medicine, School of Systems Biology George Mason University
- Alan K. Smith, Ph.D., VP of R&D and Cellular Therapeutics, LifeNet Health Institute of Regenerative Medicine
- Brian Wamhoff, Ph.D., Co-founder and VP of R&D, HemoShear Therapeutics